Brivaracetam in Children With Epilepsy: What a 12-Citation Review Found

What was studied

Researchers combined results from 12 citations on brivaracetam use in children and adolescents age 18 or younger with epilepsy.

The main outcome was retention rate, meaning how many participants continued brivaracetam. The review also examined treatment response, seizure freedom, adverse events, behavioral adverse events, and study withdrawal.

What they found

In the pooled results, the retention rate was 66%, the responder rate was 35%, and the seizure-freedom rate was 13%. Treatment-emergent adverse events were reported in 25% of patients, while behavioral adverse events were reported in 9%. The abstract does not provide the study-withdrawal rate.

Limits of the evidence

The abstract does not report the total number of participants, study designs, follow-up length, brivaracetam doses, epilepsy classifications, or whether there were comparison groups. It also does not define how much seizure reduction counted as a response or describe the specific adverse events. These missing details limit how confidently the pooled findings can be interpreted and do not establish which patients or treatment approaches are most likely to benefit.

For families and caregivers

The pooled findings suggest that some children receiving brivaracetam responded to treatment and a smaller proportion became seizure-free, while adverse events were also reported. These percentages are averages across studies and do not predict how an individual child will respond. The abstract does not show which epilepsy classifications or doses may be associated with the greatest benefit.

What to watch next

The authors call for larger studies examining brivaracetam effectiveness in different epilepsy classifications and identifying doses associated with benefit.

Terms in this summary

Brivaracetam

An antiseizure medicine evaluated in this review for children and adolescents with epilepsy.

Systematic review

A structured search and evaluation of available studies addressing a specific question.

Meta-analysis

A statistical method that combines results from multiple studies.

Retention rate

The percentage of participants who continued taking the medicine during the measured period.

Responder rate

The percentage of participants whose seizures improved by a study-defined amount; the abstract does not state that amount.

Seizure freedom

Having no seizures during the period measured by a study.

Treatment-emergent adverse event

A health problem that began or worsened after treatment started, whether or not the treatment caused it.

Behavioral adverse event

A reported unwanted event involving behavior during treatment.